Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S. Moore AS, et al. Among authors: mirabella f. Leukemia. 2012 Jul;26(7):1462-70. doi: 10.1038/leu.2012.52. Epub 2012 Feb 22. Leukemia. 2012. PMID: 22354205 Free PMC article.
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.
Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE. Fok JHL, et al. Among authors: mirabella f. Clin Cancer Res. 2018 May 15;24(10):2395-2407. doi: 10.1158/1078-0432.CCR-17-1594. Epub 2018 Feb 1. Clin Cancer Res. 2018. PMID: 29391353 Free PMC article.
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ. Walker BA, et al. Among authors: mirabella f. Leukemia. 2014 Feb;28(2):384-390. doi: 10.1038/leu.2013.199. Epub 2013 Jul 2. Leukemia. 2014. PMID: 23817176 Free PMC article.
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.
Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE. Pawlyn C, et al. Among authors: mirabella f. Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27. Blood Cancer J. 2017. PMID: 28362441 Free PMC article.
Improved risk stratification in myeloma using a microRNA-based classifier.
Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. Wu P, et al. Among authors: mirabella f. Br J Haematol. 2013 Aug;162(3):348-59. doi: 10.1111/bjh.12394. Epub 2013 May 30. Br J Haematol. 2013. PMID: 23718138 Free article.
MMSET is the key molecular target in t(4;14) myeloma.
Mirabella F, Wu P, Wardell CP, Kaiser MF, Walker BA, Johnson DC, Morgan GJ. Mirabella F, et al. Blood Cancer J. 2013 May 3;3(5):e114. doi: 10.1038/bcj.2013.9. Blood Cancer J. 2013. PMID: 23645128 Free PMC article. No abstract available.
114 results